Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Diovan/Co-Diovan

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Diovan/Co-Diovan was produced by Novartis.

It’s only money

It’s only money

It is suspected that falsified data was used in the clinical trial of Novartis’s best selling drug Diovan.

Novartis sales dip, but all eyes are on Entresto

Novartis sales dip, but all eyes are on Entresto pressure drug Diovan (valsartan) and other products such as its oestrogen patch Vivelle-Dot.

Novartis heart drug may see novel pricing plan

Novartis heart drug may see novel pricing plan The drug, which combines its now off patent blood pressure drug Diovan (valsartan) and a new antihypertensive drug sacubitril, is set for approval in August for patients with heart failure.

Heart drug sales continue downward spiral

Heart drug sales continue downward spiral Novartis has been one of the hardest hit in recent years with the patent losses of its blood pressure drug Diovan (valsartan), which was making $6bn in sales a year at

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics